Shots:
- Junshi with its subsidiary, TopAlliance, has partnered with LEO to market toripalimab in 32 EU countries incl. EEA, Switzerland & the UK. TopAlliance will remain the authorization holder overseeing development, manufacturing, registration & other activities in the EU
- LEO Pharma will handle the drug distribution, promotion & sales plus will pay an upfront & milestones on pursuing any subsequently approved indications as well as share double-digit percentage of net sales revenue
- Toripalimab (PD-1-targeting mAb) is approved by the EC & MHRA as a 1L treatment with cisplatin & gemcitabine for advanced/metastatic NPC as well as with cisplatin & paclitaxel for advanced/metastatic ESCC. BLAs are under review in countries like Singapore
Ref: Globenewswire | Image: Junshi Biosciences & LEO Pharma
Related News:- Junshi Biosciences’ Loqtorzi (Toripalimab) Receives the EC’s Approval for Treating Nasopharyngeal Carcinoma (NPC) and Esophageal Squamous Cell Carcinoma (ESCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
